Mirati Therapeutics, Inc. (NASDAQ:MRTX) has been assigned a $5.00 price objective by equities researchers at Jefferies Group LLC in a research note issued on Friday. The brokerage presently has a “hold” rating on the biotechnology company’s stock. Jefferies Group LLC’s price target would indicate a potential upside of 4.17% from the stock’s previous close.

A number of other analysts have also recently weighed in on the stock. ValuEngine upgraded shares of Mirati Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Thursday, July 6th. Zacks Investment Research cut shares of Mirati Therapeutics from a “buy” rating to a “hold” rating in a research note on Thursday, May 4th. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating and two have given a buy rating to the company. The company presently has an average rating of “Hold” and a consensus target price of $7.63.

Shares of Mirati Therapeutics (NASDAQ MRTX) opened at 4.80 on Friday. The company’s 50-day moving average is $4.02 and its 200 day moving average is $4.54. The stock’s market cap is $119.71 million. Mirati Therapeutics has a 1-year low of $2.70 and a 1-year high of $7.22.

WARNING: This piece was originally reported by Daily Political and is the sole property of of Daily Political. If you are accessing this piece on another domain, it was stolen and republished in violation of US & international trademark and copyright law. The legal version of this piece can be read at https://www.dailypolitical.com/2017/08/05/mirati-therapeutics-inc-mrtx-pt-set-at-5-00-by-jefferies-group-llc.html.

Institutional investors have recently added to or reduced their stakes in the stock. LMR Partners LLP bought a new position in Mirati Therapeutics during the second quarter valued at approximately $236,000. Boxer Capital LLC boosted its position in Mirati Therapeutics by 37.0% in the first quarter. Boxer Capital LLC now owns 1,037,994 shares of the biotechnology company’s stock valued at $5,398,000 after buying an additional 280,059 shares during the last quarter. Aviva Holdings Ltd. boosted its position in shares of Mirati Therapeutics by 44.6% in the first quarter. Aviva Holdings Ltd. now owns 2,880,702 shares of the biotechnology company’s stock worth $14,980,000 after buying an additional 888,617 shares in the last quarter. Sabby Management LLC boosted its position in shares of Mirati Therapeutics by 150.4% in the first quarter. Sabby Management LLC now owns 249,735 shares of the biotechnology company’s stock worth $1,299,000 after buying an additional 150,000 shares in the last quarter. Finally, Omega Advisors Inc. acquired a new position in shares of Mirati Therapeutics during the first quarter worth about $520,000. Hedge funds and other institutional investors own 64.56% of the company’s stock.

Analyst Recommendations for Mirati Therapeutics (NASDAQ:MRTX)

Receive News & Ratings for Mirati Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mirati Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.